
Lii Inc.
Japan · HealthTech · Undetermined

Pleryon Therapeutics
China · Biotech & life sciences · Series A
Compatibility /100
59/100
High potentialWhy talk
- Lii Inc. likely needs funding — Pleryon Therapeutics (China, Series A, $18.6M raised) can offer investor introductions (inferred from public profile).
- Pleryon Therapeutics has raised about $18.6M — investor introductions are realistic.
- Complementary sectors: HealthTech × Biotech & life sciences — room for a joint offer or co-selling.
Score anatomy
Each segment is what one dimension adds, out of 100.
Score by goal
Dimension by dimension
Needs ↔ offers
22.8 / 35 pts
Value flows both ways.
- Lii Inc. likely needs funding — Pleryon Therapeutics (China, Series A, $18.6M raised) can offer investor introductions (inferred from public profile).
- Pleryon Therapeutics likely needs first paying customers — Lii Inc. can offer access to its customer base (inferred from public profile).
Market bridge
5.0 / 10 pts
Regional bridge.
- Pleryon Therapeutics (China) is a regional neighbour in Asia — a natural first step for cross-border expansion.
Customer potential
2.5 / 5 pts
Some customer potential.
- Lii Inc. has the customers Pleryon Therapeutics is still looking for — a channel Lii Inc. can open.
Sector synergy
12.8 / 15 pts
Complementary sectors.
- Complementary sectors: HealthTech × Biotech & life sciences — room for a joint offer or co-selling.
Stage complementarity
15.7 / 35 pts
Weak stage signal.
- Pleryon Therapeutics has raised about $18.6M — investor introductions are realistic.
- Stage not comparable (Undetermined / Series A).
How the score works
Each dimension gives a value between 0 and 1, multiplied by its weight; the compatibility is the sum (0–100). Weights for “Investment”: Needs ↔ offers 35, Market bridge 10, Customer potential 5, Sector synergy 15, Stage complementarity 35. Declared needs and offers count fully; when a startup has declared nothing, a few needs/offers are inferred from its public profile (for example, no known traction ⇒ needs customers) and count at half value.
Potential blends compatibility (65%) with the mean global score of both startups (35%): 57/100 — high from 50, medium from 36.